News

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with ...
StockStory.org on MSN1h

5 Insightful Analyst Questions From Tilray’s Q2 Earnings Call

Tilray’s second quarter was met with a significant negative market reaction, as the company missed Wall Street’s revenue and ...